Leonie Mayer

Leonie Mayer

Auto-generated profile, based on publicly available information

Leonie Mayer

Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CNChristian Meyer zu Natrup
Christian Meyer zu Natrup
ATAlina Tscherne
Alina Tscherne
CDChristine Dahlke
Christine Dahlke
MCMalgorzata Ciurkiewicz
Malgorzata Ciurkiewicz
DSDai-Lun Shin
Dai-Lun Shin
AVAsisa Volz
Asisa Volz
The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and must be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus Ankara (MVA) expressing native, full-length S protein (MVA-SARS-2-S) is currently under investigation as a candidate vaccine in phase I clinical studies. Initial results from immunogenicity monitoring revealed induction of S-specific antibodies binding to S2, but low-level antibody responses to the S1 domain. Follow-up investigations of native S antigen synthesis in MVA-SARS-2-S–infected cells revealed limited levels of S1 protein on the cell surface. In contrast, we found superior S1 cell surface presentation upon infection with a recombinant MVA expressing a stabilized version of SARS-CoV-2 S protein with an inactivated S1/S2 cleavage site and K986P and V987P mutations (MVA-SARS-2-ST). When comparing immunogenicity of MVA vector vaccines, mice vaccinated with MVA-SARS-2-ST mounted substantial levels of broadly reactive anti-S antibodies that effectively neutralized different SARS-CoV-2 variants. Importantly, intramuscular MVA-SARS-2-ST immunization of hamsters and mice resulted in potent immune responses upon challenge infection and protected from disease and severe lung pathology. Our results suggest that MVA-SARS-2-ST represents an improved clinical candidate vaccine and that the presence of plasma membrane–bound S1 is highly beneficial to induce protective antibody levels.

22 December 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
SMSibylle Mellinghoff
Sibylle Mellinghoff
SRSandra Robrecht
Sandra Robrecht
LMLeonie Mayer
Leonie Mayer
LWLeonie M. Weskamm
Leonie M. Weskamm
CDChristine Dahlke
Christine Dahlke
PLPetra Langerbeins
Petra Langerbeins

26 January 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
LMLeonie Mayer
Leonie Mayer
LWLeonie M. Weskamm
Leonie M. Weskamm
AFAnahita Fathi
Anahita Fathi
MKMaya Kono
Maya Kono
JHJasmin Heidepriem
Jasmin Heidepriem
MAMarylyn M. Addo
Marylyn M. Addo
In response to the COVID-19 pandemic, multiple vaccines were developed using platforms such as viral vectors and mRNA technology. Here, we report humoral and cellular immunogenicity data from human phase 1 clinical trials investigating two recombinant Modified Vaccinia virus Ankara vaccine candidates, MVA-SARS-2-S and MVA-SARS-2-ST, encoding the native and the prefusion-stabilized SARS-CoV-2 spike protein, respectively. MVA-SARS-2-ST was more immunogenic than MVA-SARS-2-S, but both were less immunogenic compared to licensed mRNA- and ChAd-based vaccines in SARS-CoV-2 naïve individuals. In heterologous vaccination, previous MVA-SARS-2-S vaccination enhanced T cell functionality and MVA-SARS-2-ST boosted the frequency of T cells and S1-specific IgG levels when used as a third vaccination. While the vaccine candidate containing the prefusion-stabilized spike elicited predominantly S1-specific responses, immunity to the candidate with the native spike was skewed towards S2-specific responses. These data demonstrate how the spike antigen conformation, using the same viral vector, directly affects vaccine immunogenicity in humans.

20 November 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
LMLeonie Mayer
Leonie Mayer
LWLeonie M. Weskamm
Leonie M. Weskamm
MAMarylyn M. Addo
Marylyn M. Addo

4 February 2024 in European Journal of Haematology
Verified
Journal Article
Open access
SMSibylle Mellinghoff
Sibylle Mellinghoff
SRSandra Robrecht
Sandra Robrecht
RSRosanne Sprute
Rosanne Sprute
LMLeonie Mayer
Leonie Mayer
LWLeonie M. Weskamm
Leonie M. Weskamm
PLPetra Langerbeins
Petra Langerbeins
Objective: Preventing severe COVID‐19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS‐CoV‐2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL). Methods/Results: Blood samples of six patients with CLL were collected 55 days after fourth COVID‐19 vaccination. All patients had a SARS‐CoV‐2 infection within 12 months before the second booster (fourth vaccination). SARS‐CoV‐2 spike receptor binding domain (RBD)‐specific IgG antibodies were detectable in 6/6 (100.0%) CLL patients after four compared to 4/6 (66.7%) after three vaccinations. The median number of SARS‐CoV‐2 spike‐specific T cells after repeated booster vaccination plus infection was 166 spot‐forming cells (SFC) per million peripheral blood mononuclear cells. Overall, 5/5 (100%) studied patients showed a detectable increase in T cell activity. Conclusion: Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID‐19 vaccination combined with SARS‐CoV‐2 infection, even in those undergoing B cell‐depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants.

9 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLeonie Mayer
Leonie Mayer
AFAnahita Fathi
Anahita Fathi
HWHanna-Marie Weichel
Hanna-Marie Weichel
MRMatthijs Raadsen
Matthijs Raadsen
CDChristine Dahlke
Christine Dahlke
MAMarylyn M. Addo
Marylyn M. Addo
MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses. We extended this trial to assess the two-year durability of MERS-CoV-specific antibody and T cell responses in 48 study participants of the Hamburg cohort. Our findings show that immune responses remain detectable for at least 24 months after the third vaccination. Antibodies persisted at levels comparable to the peak response observed after the second vaccination and were able to cross-neutralize MERS-CoV spike mutants. Although the immune correlates of protection against MERS remain unknown, the observed durability of humoral and cellular immune responses supports the potential of MVA-MERS-S as a promising MERS vaccine candidate and highlights the importance of a booster dose in sustaining long-term immunity.